Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Vaginal Estriol Versus Prasterone in Women With Pelvic Floor Disorders
NCT07854873Completed
- Sponsor
- Poznan University of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Open-label trial of dehydroepiandrosterone in pelvic organ prolapse (POP) and stress urinary incontinence (SUI) (2 arms), sponsored by Poznan University of Medical Sciences. Primary endpoints: Change in Quality of Life Measured by WHOQOL-BREF at 8 weeks and Change in pelvic floor symptoms at 8 weeks. Started Oct 2022; status: completed.
02
Drugs
dehydroepiandrosterone
03
Conditions
pelvic organ prolapse (POP)stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT07854873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854873.